

## Rhythm Biosciences enters into a strategic collaboration for geneType™ with a global leader in Cancer Research

### Highlights

- ✓ Initiation of service agreement with Memorial Sloan Kettering Cancer Center (MSK) to support studies focused on Breast and Prostate Cancer Risk
- ✓ Contract reinstated under Rhythm Biosciences group, with continuity within the study from the team at MSK and in conjunction with Rhythm's Dr Erika Spaeth

**Melbourne, Australia, 24 July 2025:** Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX:RHY), a transformative, predictive cancer diagnostics technology company, is pleased to announce that our Genetype subsidiary business has entered into a service agreement to support clinical trials at Memorial Sloan Kettering Cancer Center (MSK), a leading cancer treatment and research institution based in New York City.

**Erika Spaeth, Scientific Director comments:** "We are excited to support high-calibre research advancing the field of polygenic risk scores. The growing body of evidence from utility and implementation studies is paving the way for clinical integration across a range of use-cases."

The geneType™ team had previously supported a clinical trial lead by Drs. Mark Robson and Jada Hamilton looking at the value of polygenic risk scores (PRS) as a breast and ovarian cancer risk modifier in BRCA1/2 carriers that began accrual in 2019.

This new service agreement supports at least two subsequent clinical trials that build on the previous work. The MSK team carrying out these studies, Drs. Ken Offit, Jada Hamilton and Mark Robson, are expanding their previous PRS modifier work in both the breast and prostate cancer field. The Rhythm team is honoured to be able to support their efforts in understanding the utility of PRS in men and women that carry BRCA1/2 mutations.

The studies are not yet underway, but based on initial accrual estimates, RHY will process at least 300 participants across both studies. Rhythm Biosciences is thrilled to support these world-class research efforts. The company is dedicated to the advancement of precision cancer prevention and remains committed to leveraging genomic risk prediction across the healthcare spectrum to enable earlier detection, informed decision-making and proactive risk reduction.

#### Directors

Otto Buttula  
Sue MacLeman  
Gavin Fox-Smith  
David Atkins

Non-Executive Chairman  
Non-Executive Director  
Non-Executive Director  
CEO & Managing Director

- ENDS -

**This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.**

**For further information contact us via [investors@rhythmbio.com](mailto:investors@rhythmbio.com).**

**About Rhythm Biosciences**

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and X.

**About ColoSTAT®**

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet relevant regulatory standards.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

**About geneType™**

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit [www.genetype.com](http://www.genetype.com).